SCHOTT Pharma records good start into fiscal year and confirms full year outlook Q1 2025 revenues reached EUR 230m; decrease of 1% yoy as reported or increase of 4% at constant currencies Q1 2025 EBITDA margin of 25.1% as reported or 26.3% at constant currencies Share of strong-margin high-value solutions (HVS) further increased to 55% Busines [ … ]

SCHOTT Pharma with successful Annual General Meeting: Shareholders approve all agenda items SCHOTT Pharma held its Annual General Meeting virtually on February 4, 2025 All items on the agenda were approved by shareholders Dr. Wolfram Carius has been appointed to SCHOTT Pharma’s Supervisory Board, replacing Dr. Wolfgang Wienand   SCHOTT Pharma,  [ … ]